Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little ...Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little known in Africa. The purpose of this study is to list all cases of hyperprolactinemia over the past four years and to make an inventory of the various etiologies found and their management. Methodology. This is a cross-sectional descriptive study on the files of patients who came for consultation in the internal medicine and endocrinology department with hyperprolactinemia retrospectively collected from January 2017 to December 2020. Included were patients followed or whose the diagnosis of hyperprolactinemia was established in endocrinological consultation during the study period. Results. This study recorded 26 cases of hyperprolactinemia. The female sex represented 73.08% (sex ratio M/F 0.37) and the average age was 33.92 years. The 40 - 50 age group was the most represented with 30.77%. In women, galactorrhea accounted for 73.07%, amenorrhea 57.69% of clinical pictures and infertility 23.08%. In men, infertility accounted for 7.69% of presentations, gynecomastia 11.54% and erectile dysfunction 15.38%. The duration of evolution of the signs was 4 months in 23.08% of the patients. The mean prolactinemia was 702.58 ng/ml. CT was performed in 80.85% of patients. The main etiologies were pituitary adenomas (77%). All our patients were treated with dopaminergic agonists. Cabergoline was prescribed in 77% of patients. The evolution was favorable in 96.25% of patients. Conclusion. Hyperprolactinemia is a pathology that exists in our regions. The main etiology remains pituitary adenomas and treatment with cabergoline.展开更多
目的:采用网络药理学和分子对接技术预测免怀散治疗高泌乳素血症(Hyperprolactinemia,HPRL)的作用靶点,并探讨其治疗HPRL的潜在作用机制和有效物质。方法:通过数据库获取免怀散的潜在活性成分及其药物靶点,并且以“Hyperprolactinemia...目的:采用网络药理学和分子对接技术预测免怀散治疗高泌乳素血症(Hyperprolactinemia,HPRL)的作用靶点,并探讨其治疗HPRL的潜在作用机制和有效物质。方法:通过数据库获取免怀散的潜在活性成分及其药物靶点,并且以“Hyperprolactinemia”为关键词在数据库中获取疾病靶点,通过Venny 2.1得到药物和疾病的共同靶点,从而构建中药有效成分靶点-疾病靶点网络。使用STRING数据库构建核心基因蛋白质-蛋白质相互作用网络。在Metascap数据库进行疾病与药物交集靶点的基因本体论(GO)功能富集分析和京都基因与基因组百科全书(KEGG)通路富集分析。最后通过“Autodock”软件对核心活性成分和核心靶点进行分子对接验证。结果:筛选得到免怀散的有效成分27个、核心靶点176个及疾病靶点228个,GO功能富集分析显示交集靶点参与了生物过程、细胞组分、分子功能等共715个生物功能条目;KEGG通路富集分析收集到113条通路,主要包括癌症通路、化学致癌作用-受体激活、酪氨酸蛋白激酶(Janus-activated Kinase,JAK)-信号转导和转录激活因子(Signal Transducer and Activator of Transcription,STAT)信号通路、癌症中的蛋白聚糖、乳腺癌、磷脂酰肌醇3激酶(Phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(Akt)信号通路、T细胞受体信号通路等。分子对接的结合能均小于-5 kcal/mol,分子对接结果良好。结论:免怀散可通过多成分、多靶点、多通路发挥治疗HPRL的作用,为临床应用免怀散治疗HPRL提供了一定的理论依据。展开更多
目的研究降乳方联合溴隐亭对特发性高催乳素(prolactin,PRL)血症月经后期的疗效。方法将60例特发性高PRL血症月经后期患者随机分为治疗组(30例)和对照组(30例),治疗组给予降乳方加溴隐亭,对照组给予溴隐亭,比较两组治疗后的血清PRL、雌...目的研究降乳方联合溴隐亭对特发性高催乳素(prolactin,PRL)血症月经后期的疗效。方法将60例特发性高PRL血症月经后期患者随机分为治疗组(30例)和对照组(30例),治疗组给予降乳方加溴隐亭,对照组给予溴隐亭,比较两组治疗后的血清PRL、雌二醇(estradiol,E2)、卵泡刺激素(follicle-stimulating hormone,FSH)、黄体生成素(luteinizing hormone,LH)水平,月经积分,中医证候积分,基础体温(basal body temperature,BBT),疗效,用药不良反应及停药后复发率。结果治疗后,两组血清PRL水平均降低,E2、FSH、LH水平及BBT双向率均升高,差异有统计学意义(P<0.01);且治疗组月经积分及中医证候积分均低于对照组,差异有统计学意义(P<0.01);治疗组中医证候疗效总有效率96.67%高于对照组的80%,总体疗效的有效率96.67%高于对照组的73.33%,差异均具有统计学意义(P<0.05);治疗组不良反应发生率为6.67%,低于对照组的26.67%,且治疗组复发率为6.67%,低于对照组的37.04%,差异均具有统计学意义(P<0.05)。结论降乳方联合溴隐亭可使高PRL血症月经后期患者体内PRL水平降低,使E2、FSH、LH水平升高,使中医证候积分降低,调整月经周期,提高排卵率,提高临床疗效,用药安全性高,停药后复发率低。展开更多
文摘Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little known in Africa. The purpose of this study is to list all cases of hyperprolactinemia over the past four years and to make an inventory of the various etiologies found and their management. Methodology. This is a cross-sectional descriptive study on the files of patients who came for consultation in the internal medicine and endocrinology department with hyperprolactinemia retrospectively collected from January 2017 to December 2020. Included were patients followed or whose the diagnosis of hyperprolactinemia was established in endocrinological consultation during the study period. Results. This study recorded 26 cases of hyperprolactinemia. The female sex represented 73.08% (sex ratio M/F 0.37) and the average age was 33.92 years. The 40 - 50 age group was the most represented with 30.77%. In women, galactorrhea accounted for 73.07%, amenorrhea 57.69% of clinical pictures and infertility 23.08%. In men, infertility accounted for 7.69% of presentations, gynecomastia 11.54% and erectile dysfunction 15.38%. The duration of evolution of the signs was 4 months in 23.08% of the patients. The mean prolactinemia was 702.58 ng/ml. CT was performed in 80.85% of patients. The main etiologies were pituitary adenomas (77%). All our patients were treated with dopaminergic agonists. Cabergoline was prescribed in 77% of patients. The evolution was favorable in 96.25% of patients. Conclusion. Hyperprolactinemia is a pathology that exists in our regions. The main etiology remains pituitary adenomas and treatment with cabergoline.
文摘目的:采用网络药理学和分子对接技术预测免怀散治疗高泌乳素血症(Hyperprolactinemia,HPRL)的作用靶点,并探讨其治疗HPRL的潜在作用机制和有效物质。方法:通过数据库获取免怀散的潜在活性成分及其药物靶点,并且以“Hyperprolactinemia”为关键词在数据库中获取疾病靶点,通过Venny 2.1得到药物和疾病的共同靶点,从而构建中药有效成分靶点-疾病靶点网络。使用STRING数据库构建核心基因蛋白质-蛋白质相互作用网络。在Metascap数据库进行疾病与药物交集靶点的基因本体论(GO)功能富集分析和京都基因与基因组百科全书(KEGG)通路富集分析。最后通过“Autodock”软件对核心活性成分和核心靶点进行分子对接验证。结果:筛选得到免怀散的有效成分27个、核心靶点176个及疾病靶点228个,GO功能富集分析显示交集靶点参与了生物过程、细胞组分、分子功能等共715个生物功能条目;KEGG通路富集分析收集到113条通路,主要包括癌症通路、化学致癌作用-受体激活、酪氨酸蛋白激酶(Janus-activated Kinase,JAK)-信号转导和转录激活因子(Signal Transducer and Activator of Transcription,STAT)信号通路、癌症中的蛋白聚糖、乳腺癌、磷脂酰肌醇3激酶(Phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(Akt)信号通路、T细胞受体信号通路等。分子对接的结合能均小于-5 kcal/mol,分子对接结果良好。结论:免怀散可通过多成分、多靶点、多通路发挥治疗HPRL的作用,为临床应用免怀散治疗HPRL提供了一定的理论依据。
文摘目的研究降乳方联合溴隐亭对特发性高催乳素(prolactin,PRL)血症月经后期的疗效。方法将60例特发性高PRL血症月经后期患者随机分为治疗组(30例)和对照组(30例),治疗组给予降乳方加溴隐亭,对照组给予溴隐亭,比较两组治疗后的血清PRL、雌二醇(estradiol,E2)、卵泡刺激素(follicle-stimulating hormone,FSH)、黄体生成素(luteinizing hormone,LH)水平,月经积分,中医证候积分,基础体温(basal body temperature,BBT),疗效,用药不良反应及停药后复发率。结果治疗后,两组血清PRL水平均降低,E2、FSH、LH水平及BBT双向率均升高,差异有统计学意义(P<0.01);且治疗组月经积分及中医证候积分均低于对照组,差异有统计学意义(P<0.01);治疗组中医证候疗效总有效率96.67%高于对照组的80%,总体疗效的有效率96.67%高于对照组的73.33%,差异均具有统计学意义(P<0.05);治疗组不良反应发生率为6.67%,低于对照组的26.67%,且治疗组复发率为6.67%,低于对照组的37.04%,差异均具有统计学意义(P<0.05)。结论降乳方联合溴隐亭可使高PRL血症月经后期患者体内PRL水平降低,使E2、FSH、LH水平升高,使中医证候积分降低,调整月经周期,提高排卵率,提高临床疗效,用药安全性高,停药后复发率低。
